摘要:
A process is provided for preparing isoprenoid cyclopropane 1,1-dicarboxylates which are useful in preparing squalene synthetase inhibitors which inhibit cholesterol biosynthesis, and also useful in preparing pyrethrin insecticides.
摘要:
A process is provided for preparing isoprenoid cyclopropane 1,1-dicarboxylates and derivatives thereof including the corresponding monocarboxylate, monocarboxylic acid and alcohol derivatives thereof, all of which are useful in preparing squalene synthetase inhibitors which inhibit cholesterol biosynthesis, and also useful in preparing pyrethrin insecticides.
摘要:
A process is provided for preparing isoprenoid cyclopropane 1,1-dicarboxylates and derivatives thereof including the corresponding monocarboxylate, monocarboxylic acid and alcohol derivatives thereof, all of which are useful in preparing squalene synthetase inhibitors which inhibit cholesterol biosynthesis, and also useful in preparing pyrethrin insecticides.
摘要:
Disclosed herein is a method for making compounds that are useful as caspase inhibitor prodrugs of formula I: wherein R1 is an optionally substituted group selected from an aliphatic group, aralkyl group, heterocyclylalkyl group or aryl group, and R2 is preferably a P2—P4 moiety of a caspase inhibitor. Key intermediates include the azidolactones III and VIII:
摘要翻译:本文公开了一种制备可用作式I的半胱天冬酶抑制剂前药的化合物的方法:其中R 1是选自脂族基团,芳烷基,杂环基烷基或芳基的任选取代的基团,和 R 2优选是半胱天冬酶抑制剂的P 2 -P 4 N 4个部分。 主要中间体包括叠氮内酯III和VIII:
摘要:
This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译:本发明描述了式IV的新型吡唑化合物:其中环D是5-7元单环或选自芳基,杂芳基,杂环基或碳环基的8-10元双环; R x和R y独立地选自TR 3,或者与它们的插入原子一起形成具有1-3个选自氧,C 1 -C 6烷基的环杂原子的稠合,不饱和或部分不饱和的5-8元环, 硫或氮; R 2,R 2,T和R 3如说明书中所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病的极光-2和GSK-3的抑制剂。
摘要:
This invention describes novel pyrazole compounds of formula II: wherein Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, and R2, R2′, Rx, and Ry are as described in the specification. Ring C has an ortho substituent and is optionally substituted in the non-ortho positions. R2 and R2′ are optionally taken together with their intervening atoms to form a fused ring system, such as an indazole ring; and Rx and Ry are optionally taken together with their intervening atoms to form a fused ring system, such as a quinazoline ring. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3, for treating diseases such as diabetes and Alzheimer's disease.
摘要:
The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
摘要:
The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders
摘要:
The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The compounds are generally represented by structural formula I or pharmaceutically acceptable salts thereof:
摘要:
This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
摘要翻译:本发明描述了式IV的新型吡唑化合物:其中环D是5-7元单环或选自芳基,杂芳基,杂环基或碳环基的8-10元双环; R x和R y独立地选自T-R 3,或与它们的插入原子一起形成具有1-3个选自氧,硫或氮的环杂原子的稠合的,不饱和的或部分不饱和的5-8元环; R2,R2',T和R3如说明书中所述。 这些化合物可用作蛋白激酶抑制剂,特别是作为用于治疗诸如癌症,糖尿病和阿尔茨海默病的疾病的极光-2和GSK-3的抑制剂。